Published Date: 04 Mar 2024
While one first-line regimen provided an extra option, another resulted in a worse operating system.
Read Full NewsTest your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on FcRn-blocking therapies in neurology!
Andrea Rossetti, MD, director of the EEG/Epilepsy Unit at the Department of Clinical Neurosciences the Lausanne University Hospital in Switzerland, offers insight into post-resuscitation epilepsy care.
Here's some of what is coming soon to NeurologyLive® this week.
Orelabrutinib Achieves Primary Endpoint in Phase 2b SLE Trial
Getting Through the Door: How COPD, Lung Cancer Screening Remains Minimal
Phase 3 VALIANT Results for Pegcetacoplan In C3G, IC-MPGN, With Andrew Bomback, MD
Intensive Weight Loss Before Colorectal Cancer Surgery Safe, Feasible
1.
High levels of traumatic stress found in caregivers of adult cancer patients
2.
In Relapsed/Refractory Myeloma, Blenrep-Based Regimen Produces PFS Advantage.
3.
Chronic stress and obesity work together to accelerate pancreatic cancer development and growth, study finds
4.
The top three drugs for multiple myeloma treatment upfront are four.
5.
Reduced Suicide Rates in Cancer Patients; Enhanced Circadian Rhythm; HIV Vaccine for Cancer Patients?
1.
Unlocking the Benefits of Eltrombopag: A Comprehensive Guide
2.
Unleashing Precision Medicine: CRISPR-Cas9 Gene Editing in Hematopoietic Stem Cells
3.
CEUS in Endometrial Cancer: A Tool for Early Myometrial Infiltration Detection
4.
The Danger of Rectus Sheath Hematoma: A Hidden Risk of Abdominal Surgery
5.
Navigating the Stages of Thyroid Cancer: A Guide for Patients
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC
2.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation